280 related articles for article (PubMed ID: 34794988)
21. Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020.
Durand L; Keenan E; O'Reilly D; Bennett K; O'Hara A; Cousins G
BMC Psychiatry; 2023 Oct; 23(1):725. PubMed ID: 37803285
[TBL] [Abstract][Full Text] [Related]
22. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
[TBL] [Abstract][Full Text] [Related]
23. Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting.
Mitchell M
J Correct Health Care; 2021 Sep; 27(3):210-214. PubMed ID: 34388040
[TBL] [Abstract][Full Text] [Related]
24. Opioid toxicity deaths in Black persons who experienced provincial incarceration in Ontario, Canada 2015-2020: A population-based study.
Owusu-Bempah A; Nicholson HL; Butler A; Croxford R; Kouyoumdjian FG
Prev Med; 2023 Dec; 177():107778. PubMed ID: 37967621
[TBL] [Abstract][Full Text] [Related]
25. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
[TBL] [Abstract][Full Text] [Related]
26. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
[TBL] [Abstract][Full Text] [Related]
27. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
[TBL] [Abstract][Full Text] [Related]
29. Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses.
Bi-Mohammed Z; Wright NM; Hearty P; King N; Gavin H
Drug Alcohol Depend; 2017 Feb; 171():122-131. PubMed ID: 28086177
[TBL] [Abstract][Full Text] [Related]
30. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
Wright NM; Mohammed Z; Hughes GJ
Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
[TBL] [Abstract][Full Text] [Related]
31. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
[TBL] [Abstract][Full Text] [Related]
32. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
[TBL] [Abstract][Full Text] [Related]
33. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
[TBL] [Abstract][Full Text] [Related]
34. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
35. History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
Hallowell BD; Weidele HR; Daly M; Chambers LC; Scagos RP; Gargano L; McDonald J
Am J Public Health; 2021 Sep; 111(9):1600-1603. PubMed ID: 34410818
[TBL] [Abstract][Full Text] [Related]
36. Infants Born to Opioid-Dependent Women in Ontario, 2002-2014.
Brogly SB; Turner S; Lajkosz K; Davies G; Newman A; Johnson A; Dow K
J Obstet Gynaecol Can; 2017 Mar; 39(3):157-165. PubMed ID: 28343557
[TBL] [Abstract][Full Text] [Related]
37. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
[TBL] [Abstract][Full Text] [Related]
38. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of opioid maintenance programs for treating drug dependence in prisons.
Roselló-Jordá S; Espinós-Navarro C; Molés-Julio MP
Rev Esp Sanid Penit; 2023; 25(3):112-121. PubMed ID: 38289166
[TBL] [Abstract][Full Text] [Related]
40. Use and misuse of opioid agonists in opioid addiction.
Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
